The IncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer

John R. Prensner, Anirban Sahu, Matthew K. Iyer, Rohit Malik, Benjamin Chandler, Irfan A. Asangani, Anton Poliakov, Ismael A. Vergara, Mohammed Alshalalfa, Robert Brian Jenkins, Elai Davicioni, Felix Y. Feng, Arul M. Chinnaiyan

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Long noncoding RNAs (IncRNAs) are increasingly implicated in cancer biology, contributing to essential cancer cell functions such as proliferation, invasion, and metastasis. In prostate cancer, several IncRNAs have been nominated as critical actors in disease pathogenesis. Among these, expression of PCGEM1 and PRNCR1 has been identified as a possible component in disease progression through the coordination of androgen receptor (AR) signaling (Yang et al., Nature 2013, see ref. [1]). However, concerns regarding the robustness of these findings have been suggested. Here, we sought to evaluate whether PCGEM1 and PRNCR1 are associated with prostate cancer. Through a comprehensive analysis of RNA-sequencing data (RNA-seq), we find evidence that PCGEM1 but not PRNCR1 is associated with prostate cancer. We employ a large cohort of >230 high-risk prostate cancer patients with long-term outcomes data to show that, in contrast to prior reports, neither gene is associated with poor patient outcomes. We further observe no evidence that PCGEM1 nor PRNCR1 interact with AR, and neither gene is a component of AR signaling. Thus, we conclusively demonstrate that PCGEM1 and PRNCR1 are not prognostic IncRNAs in prostate cancer and we refute suggestions that these IncRNAs interact in AR signaling.

Original languageEnglish (US)
Pages (from-to)1434-1438
Number of pages5
JournalOncotarget
Volume5
Issue number6
StatePublished - 2014

Fingerprint

Castration
Androgen Receptors
Prostatic Neoplasms
Long Noncoding RNA
RNA Sequence Analysis
Genes
Disease Progression
Neoplasms
RNA
Neoplasm Metastasis

Keywords

  • Androgen receptor
  • Long noncoding RNA
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Medicine(all)

Cite this

Prensner, J. R., Sahu, A., Iyer, M. K., Malik, R., Chandler, B., Asangani, I. A., ... Chinnaiyan, A. M. (2014). The IncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer. Oncotarget, 5(6), 1434-1438.

The IncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer. / Prensner, John R.; Sahu, Anirban; Iyer, Matthew K.; Malik, Rohit; Chandler, Benjamin; Asangani, Irfan A.; Poliakov, Anton; Vergara, Ismael A.; Alshalalfa, Mohammed; Jenkins, Robert Brian; Davicioni, Elai; Feng, Felix Y.; Chinnaiyan, Arul M.

In: Oncotarget, Vol. 5, No. 6, 2014, p. 1434-1438.

Research output: Contribution to journalArticle

Prensner, JR, Sahu, A, Iyer, MK, Malik, R, Chandler, B, Asangani, IA, Poliakov, A, Vergara, IA, Alshalalfa, M, Jenkins, RB, Davicioni, E, Feng, FY & Chinnaiyan, AM 2014, 'The IncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer', Oncotarget, vol. 5, no. 6, pp. 1434-1438.
Prensner JR, Sahu A, Iyer MK, Malik R, Chandler B, Asangani IA et al. The IncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer. Oncotarget. 2014;5(6):1434-1438.
Prensner, John R. ; Sahu, Anirban ; Iyer, Matthew K. ; Malik, Rohit ; Chandler, Benjamin ; Asangani, Irfan A. ; Poliakov, Anton ; Vergara, Ismael A. ; Alshalalfa, Mohammed ; Jenkins, Robert Brian ; Davicioni, Elai ; Feng, Felix Y. ; Chinnaiyan, Arul M. / The IncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer. In: Oncotarget. 2014 ; Vol. 5, No. 6. pp. 1434-1438.
@article{fb53c97b5b9a40a0beafe9a86cd3ee25,
title = "The IncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer",
abstract = "Long noncoding RNAs (IncRNAs) are increasingly implicated in cancer biology, contributing to essential cancer cell functions such as proliferation, invasion, and metastasis. In prostate cancer, several IncRNAs have been nominated as critical actors in disease pathogenesis. Among these, expression of PCGEM1 and PRNCR1 has been identified as a possible component in disease progression through the coordination of androgen receptor (AR) signaling (Yang et al., Nature 2013, see ref. [1]). However, concerns regarding the robustness of these findings have been suggested. Here, we sought to evaluate whether PCGEM1 and PRNCR1 are associated with prostate cancer. Through a comprehensive analysis of RNA-sequencing data (RNA-seq), we find evidence that PCGEM1 but not PRNCR1 is associated with prostate cancer. We employ a large cohort of >230 high-risk prostate cancer patients with long-term outcomes data to show that, in contrast to prior reports, neither gene is associated with poor patient outcomes. We further observe no evidence that PCGEM1 nor PRNCR1 interact with AR, and neither gene is a component of AR signaling. Thus, we conclusively demonstrate that PCGEM1 and PRNCR1 are not prognostic IncRNAs in prostate cancer and we refute suggestions that these IncRNAs interact in AR signaling.",
keywords = "Androgen receptor, Long noncoding RNA, Prostate cancer",
author = "Prensner, {John R.} and Anirban Sahu and Iyer, {Matthew K.} and Rohit Malik and Benjamin Chandler and Asangani, {Irfan A.} and Anton Poliakov and Vergara, {Ismael A.} and Mohammed Alshalalfa and Jenkins, {Robert Brian} and Elai Davicioni and Feng, {Felix Y.} and Chinnaiyan, {Arul M.}",
year = "2014",
language = "English (US)",
volume = "5",
pages = "1434--1438",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "6",

}

TY - JOUR

T1 - The IncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer

AU - Prensner, John R.

AU - Sahu, Anirban

AU - Iyer, Matthew K.

AU - Malik, Rohit

AU - Chandler, Benjamin

AU - Asangani, Irfan A.

AU - Poliakov, Anton

AU - Vergara, Ismael A.

AU - Alshalalfa, Mohammed

AU - Jenkins, Robert Brian

AU - Davicioni, Elai

AU - Feng, Felix Y.

AU - Chinnaiyan, Arul M.

PY - 2014

Y1 - 2014

N2 - Long noncoding RNAs (IncRNAs) are increasingly implicated in cancer biology, contributing to essential cancer cell functions such as proliferation, invasion, and metastasis. In prostate cancer, several IncRNAs have been nominated as critical actors in disease pathogenesis. Among these, expression of PCGEM1 and PRNCR1 has been identified as a possible component in disease progression through the coordination of androgen receptor (AR) signaling (Yang et al., Nature 2013, see ref. [1]). However, concerns regarding the robustness of these findings have been suggested. Here, we sought to evaluate whether PCGEM1 and PRNCR1 are associated with prostate cancer. Through a comprehensive analysis of RNA-sequencing data (RNA-seq), we find evidence that PCGEM1 but not PRNCR1 is associated with prostate cancer. We employ a large cohort of >230 high-risk prostate cancer patients with long-term outcomes data to show that, in contrast to prior reports, neither gene is associated with poor patient outcomes. We further observe no evidence that PCGEM1 nor PRNCR1 interact with AR, and neither gene is a component of AR signaling. Thus, we conclusively demonstrate that PCGEM1 and PRNCR1 are not prognostic IncRNAs in prostate cancer and we refute suggestions that these IncRNAs interact in AR signaling.

AB - Long noncoding RNAs (IncRNAs) are increasingly implicated in cancer biology, contributing to essential cancer cell functions such as proliferation, invasion, and metastasis. In prostate cancer, several IncRNAs have been nominated as critical actors in disease pathogenesis. Among these, expression of PCGEM1 and PRNCR1 has been identified as a possible component in disease progression through the coordination of androgen receptor (AR) signaling (Yang et al., Nature 2013, see ref. [1]). However, concerns regarding the robustness of these findings have been suggested. Here, we sought to evaluate whether PCGEM1 and PRNCR1 are associated with prostate cancer. Through a comprehensive analysis of RNA-sequencing data (RNA-seq), we find evidence that PCGEM1 but not PRNCR1 is associated with prostate cancer. We employ a large cohort of >230 high-risk prostate cancer patients with long-term outcomes data to show that, in contrast to prior reports, neither gene is associated with poor patient outcomes. We further observe no evidence that PCGEM1 nor PRNCR1 interact with AR, and neither gene is a component of AR signaling. Thus, we conclusively demonstrate that PCGEM1 and PRNCR1 are not prognostic IncRNAs in prostate cancer and we refute suggestions that these IncRNAs interact in AR signaling.

KW - Androgen receptor

KW - Long noncoding RNA

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84904268650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904268650&partnerID=8YFLogxK

M3 - Article

C2 - 24727738

AN - SCOPUS:84904268650

VL - 5

SP - 1434

EP - 1438

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 6

ER -